宝莱特 reported revenue of ¥0.52B for the period ended 2026-06-30, -1.1% year on year. Net income was ¥-0.04B, a -6.8% net margin on a 22.9% gross margin. The largest revenue line is 血透产品 at 76% of the total. Free cash flow for the period was ¥0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.52B | -1.1% |
| Gross profit | ¥0.12B | — |
| Operating income | ¥-0.04B | — |
| Net income | ¥-0.04B | -845.3% |
| Gross margin | 22.9% | Net margin -6.8% |
| Revenue Q/Q | +13.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 血透产品 | ¥0.39B | 75.6% |
| 监护仪产品 | ¥0.12B | 23.4% |
| 其他(补充) | ¥0.01B | 1.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.40B | 77.1% |
| R&D | ¥0.03B | 6.2% |
| SG&A | ¥0.11B | 21.8% |
| Tax & other | ¥-0.00B | -0.5% |
| Item | Amount |
|---|---|
| Total assets | ¥2.45B |
| Total liabilities | ¥1.28B |
| Shareholders' equity | ¥1.18B |
| Equity / assets | 47.9% |
| Operating cash flow | ¥0.08B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.06B |
| Cash conversion (OCF / net income) | -191% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
融捷健康 ・ 新开普 ・ 依米康 ・ 初灵信息 ・ 金信诺 ・ 卫宁健康 ・ 仟源医药 ・ 常山药业 ・ 星星科技 ・ 开山股份 ・ 精锻科技 ・ 新天科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies